Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.
[More]
Tumor necrosis factor - normally an infection-fighting substance produced by the body- can actually heighten susceptibility to tuberculosis if its levels are too high.
[More]
Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.
[More]
Enlarged lymph nodes are a marker for both occult cancer and a long-term risk for malignancy, confirms research published in the British Journal of Haematology.
[More]
Primary sclerosing cholangitis patients with concomitant immunologic disorders, have reduced transplantation-free survival compared with patients without, say the authors of a German study.
[More]
People who are exposed to mold in their homes could be at an increased risk for sarcoidosis, a chronic inflammatory lung disease. Researchers from Sweden and Slovenia tested 62 nonsmoking patients with sarcoidosis, 34 of whom had extrapulmonary manifestations (EPM).
[More]
Researchers at the University of Illinois Hospital & Health Sciences System have identified a genetic signature that distinguishes patients with complicated sarcoidosis, an inflammatory lung disease that can be fatal, from patients with a more benign form of the disease. The gene signature could become the basis for a simple blood test.
[More]
A new study conducted by researchers from Boston University has found that sarcoidosis accounts for 25 percent of all deaths among women in the Black Women's Health Study who have the disease. The study is the largest epidemiologic study to date to specifically address mortality in black females with sarcoidosis.
[More]
With a range of diseases, doctors need unique features which they can use to unequivocally identify a patient's illness for an appropriate diagnosis. Scientists therefore search for the biomarkers for an illness or a combination of biomarkers, known as biosignatures, which are as easy as possible to measure.
[More]
Patricia F. Coogan, ScD, an associate professor of epidemiology at Boston University's Slone Epidemiology Center (SEC), recently was awarded funding for two grants from the National Institutes of Health.
[More]
Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.
[More]
Merck, known as MSD outside of the United States and Canada, announced today that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.
[More]
Mount Sinai researchers coordinating the largest clinical study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in World Trade Center (WTC) responders have found that the rate of the condition was increased in this group as compared to the records of pre-9/11 FDNY personnel. The study is published online in the American Journal of Industrial Medicine.
[More]
New research suggests that subcutaneous omalizumab is safe and effective an add-on treatment to corticosteroids for moderate to severe asthma in children and adults. Researchers from Uruguay, Argentina, and Chile performed a meta-analysis on eight trials where 1,883 patients received omalizumab and 1,546 received a placebo.
[More]
A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.
[More]
Questcor Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood.
[More]
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
[More]
Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.
[More]
Merck today announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
[More]
Twelve dermatology residents from leading medical schools around the country each received a $40,000, one-year fellowship grant to study medical dermatology. The fellowships, awarded by the National Psoriasis Foundation, provide support to eligible institutions to develop and enhance opportunities for physicians training for careers in medical dermatology.
[More]